Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]

Status:

Topic prioritisation

Technology type:

Medicine

Decision:

Not selected

Prioritisation programme:

Medicines evaluation

Rationale:

The NICE-Wide Prioritisation Board met on 22 January 2026 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers concluded that the clear rationale to not evaluate this product is due to commissioning under the NHS England commissioning medicines for children in specialised services policy being appropriate with Ponatinib being a paediatric extension of TA451. Please see eligibility criteria within the prioritisation manual for further information.

Project Team

Project lead

Danielle Lees

Timeline

Key events during the development of the guidance:

For further information on how we select topics for development, please see our page about topic prioritisation